Zepbound vs Mounjaro: Same Drug, Different Labels, Which Is Right for You?

Zepbound and Mounjaro are the same drug, tirzepatide, sold under different brand names for different FDA-approved uses.

Mounjaro was approved by the FDA in May 2022 for Type 2 diabetes.

Zepbound was approved November 2023 for chronic weight management and December 2024 for obstructive sleep apnea, the first drug ever approved for OSA.

Same molecule, same doses (2.5 mg to 15 mg weekly), same side effects, same manufacturer (Eli Lilly). List prices are about $1,086 to $1,112 a month.

With commercial insurance and manufacturer savings cards, both drop to $25/month (max $1,950/year).

Which one fits you:

• •You have type 2 diabetes: Mounjaro is the FDA-labeled drug your insurance is likely to cover.
• •You have obesity, or a BMI of 27+ with a weight-related condition: Zepbound is the FDA-labeled drug for you, and your diagnosis code, not your goal, decides which brand insurance pays for.
• •You're paying cash: Zepbound, because LillyDirect sells single-dose vials at $299-$449/mo and Mounjaro has no equivalent self-pay vial program.
• •You have both conditions: your provider picks one based on your primary diagnosis and your insurance formulary.
• •You're comparing compounded options at $99-$199/mo: see our cheapest tirzepatide guide. Compounded tirzepatide is not FDA-approved.

How much do Zepbound and Mounjaro cost?

The current manufacturer list prices differ: Mounjaro is $1,112.16/month and Zepbound is about $1,086/month. Insurance and manufacturer-program eligibility can change what an individual actually pays. The key differences:

The biggest cash-pay difference: Zepbound has LillyDirect single-dose vials at $299-$449/month, saving $650-$800/month vs the list price.

Mounjaro does not have an equivalent self-pay vial program.

Mounjaro patients without coverage pay from $499/mo for the pen, through LillyDirect self-pay or the Mounjaro Savings Card when a commercial plan does not cover it.

For self-paying patients, Zepbound is meaningfully cheaper.

For Medicare beneficiaries, the GLP-1 Bridge program is separate from ordinary Part D and includes only Zepbound KwikPen, not its single-dose pens or vials.

Eligible patients pay $50 per monthly supply after authorization.

Mounjaro is not a Bridge product; coverage for its diabetes indication follows the individual's Part D plan. Medicare's covered products and rules.

Does insurance cover Zepbound or Mounjaro?

It depends on your diagnosis.

Mounjaro is covered by most commercial plans for Type 2 diabetes and typically denied for weight loss, while Zepbound is covered by the roughly 50-60% of commercial plans that include weight-management benefits, plus some that cover sleep apnea instead.

Insurance companies cover drugs by FDA-approved indication, not by molecular identity. Your insurance plan has a formulary (list of covered drugs) and prior authorization criteria tied to specific diagnoses.

This is where Mounjaro and Zepbound diverge sharply:

• •Commercial insurance, Type 2 diabetes: Mounjaro is covered by most commercial plans under the diabetes benefit. Zepbound is not covered for diabetes; attempting to fill Zepbound with a diabetes diagnosis will typically be denied.
• •Commercial insurance, obesity/weight management: Zepbound is covered by plans that include weight-management benefits (roughly 50-60% of commercial plans as of 2026). Mounjaro is not covered for weight loss; attempting to fill Mounjaro with an obesity-only diagnosis will typically be denied.
• •Commercial insurance, obstructive sleep apnea: Zepbound's OSA indication can expand coverage to plans that exclude weight-management but cover OSA treatments. This is Zepbound's biggest insurance advantage over Mounjaro.
• •Medicare Part D, diabetes: Mounjaro covered since 2022. Zepbound not covered under a diabetes indication.
• •Medicare, weight management: Basic Part D's weight-loss exclusion remains. The separate Medicare GLP-1 Bridge launched July 1, 2026 and can provide Zepbound KwikPen at $50 per monthly supply for eligible patients. Mounjaro is not included.
• •Medicaid: Coverage varies by state. Mounjaro is covered in most states for Type 2 diabetes. Zepbound coverage for weight loss is more limited, see our state-by-state Medicaid GLP-1 coverage map.
• •Prior authorization: Required by most insurers for both. Typical criteria for Zepbound: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (Type 2 diabetes, hypertension, dyslipidemia, sleep apnea, cardiovascular disease). Typical criteria for Mounjaro: diagnosed Type 2 diabetes with A1C above target despite other medications.

Who should get Mounjaro?

• •You have Type 2 diabetes and need glycemic control: this is the FDA-labeled indication and covered by most commercial insurance and Medicare Part D
• •You have both Type 2 diabetes and obesity, and your provider uses the diabetes indication for coverage; Mounjaro will address both A1C and weight
• •Your commercial insurance formulary prefers Mounjaro over other diabetes medications (formulary preferences vary by plan)
• •You're stable on Ozempic or Trulicity and want to switch to a dual GIP/GLP-1 agonist for better A1C control or additional weight loss benefit

Who should get Zepbound?

• •Your primary diagnosis is obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related condition: this is the FDA-labeled indication
• •You have moderate-to-severe obstructive sleep apnea with obesity: Zepbound is the only tirzepatide product approved for OSA, and this indication can expand insurance coverage
• •You're paying out-of-pocket and want the lowest price: LillyDirect single-dose vials at $299-$449/month are significantly cheaper than Mounjaro's self-pay pen price of $499/month
• •You're on Medicare: since July 2026 the GLP-1 Bridge program covers Zepbound KwikPen at $50/month for eligible enrollees
• •Your commercial insurance covers weight-management medications and includes Zepbound on its formulary

What if neither one is covered?

If Wegovy is covered by your insurance and Zepbound isn't, Wegovy is the practical alternative when tirzepatide coverage is denied.

It produced less weight loss on average: 13.7% against 20.2% for tirzepatide in the SURMOUNT-5 head-to-head trial.

For the cheapest paths to tirzepatide, including compounded alternatives through telehealth platforms, see our cheapest tirzepatide providers guide or take the match quiz for a personalized recommendation based on your budget, insurance, and goals.

Why do Zepbound and Mounjaro have different names?

Because Eli Lilly filed two separate New Drug Applications, one per indication.

The same tirzepatide is branded Mounjaro for Type 2 diabetes and Zepbound for chronic weight management, each backed by its own trial program and reviewed by the FDA on its own.

Tirzepatide is a once-weekly injectable peptide developed by Eli Lilly.

It's the first medication to activate both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors, a dual-agonist design that distinguishes it from older GLP-1-only drugs like semaglutide (sold as Ozempic, Wegovy, and Rybelsus).

For a deeper look at the two drug classes, see our semaglutide vs tirzepatide comparison.

Lilly filed two separate New Drug Applications with the FDA: one for tirzepatide as a Type 2 diabetes treatment (branded Mounjaro) and one for tirzepatide as a chronic weight management treatment (branded Zepbound).

Each application had its own trial program: SURPASS-1 through SURPASS-5 for diabetes and SURMOUNT-1 through SURMOUNT-5 for obesity. The FDA evaluates each application independently.

Even though the molecule is the same, the two products are legally distinct.

This is common in US drug naming: the brand follows the use. The same pattern applies to other drugs: bupropion is sold as Wellbutrin for depression and Zyban for smoking cessation.

Finasteride is sold as Proscar (5 mg, prostate) and Propecia (1 mg, hair loss). Tirzepatide simply has two labels, diabetes and weight/OSA.

When was each one approved?

Tirzepatide has three FDA approvals across two brand names:

• •May 13, 2022, Mounjaro approved for Type 2 diabetes. Indication: adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus. Approval based on the SURPASS clinical trial program, which showed tirzepatide 15 mg lowered A1C by ~2.0-2.5 percentage points with average weight loss of ~10-12% as a secondary outcome.
• •November 8, 2023, Zepbound approved for chronic weight management. Indication: adjunct to a reduced-calorie diet and increased physical activity for long-term weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. Approval based on the SURMOUNT-1 trial showing 20.9% average weight loss at the 15 mg dose over 72 weeks.
• •December 20, 2024, Zepbound approved for obstructive sleep apnea. Indication: moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, the first drug ever approved for OSA. Approval based on the SURMOUNT-OSA trial, which showed tirzepatide reduced apnea-hypopnea index (the standard measure of OSA severity) substantially compared to placebo. This is a Zepbound-only indication; Mounjaro's label does not include OSA.

The Mounjaro label covers only Type 2 diabetes. The Zepbound label covers chronic weight management AND obstructive sleep apnea.

A patient with obesity and sleep apnea would be prescribed Zepbound under its OSA indication, which may open insurance coverage pathways that weight-loss-only coverage doesn't.

Is the dosing the same?

Because Mounjaro and Zepbound are the same molecule, they share the exact same dose titration schedule.

Both are once-weekly subcutaneous injections with the same starter dose, escalation path, and maximum dose (see our full tirzepatide dosage chart for every dose level and week-by-week timing):

The manufacturer recommends each dose be maintained for at least 4 weeks before escalation to reduce GI side effects. Most providers reach the 5 mg or 10 mg maintenance dose by month 3-5, then hold or escalate based on response.

The 12.5 mg and 15 mg doses are typically reserved for patients who haven't reached their treatment goal at lower doses.

Are the side effects the same?

Because the molecule is identical, the side effect profile is identical. Stomach side effects are the most common: nausea, diarrhea, vomiting and constipation, which peak while the dose is going up.

Rates from the Zepbound prescribing information and SURMOUNT trials:

For a full breakdown of side effects, management strategies, and when to call your doctor, see our Zepbound side effects guide.

Both medications carry the same FDA boxed warning about thyroid C-cell tumors (based on animal studies) and the same contraindications for patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Can You Switch Between Mounjaro and Zepbound?

Switching between Mounjaro and Zepbound is essentially switching the label on the same drug, so there's no pharmacological transition period. Most providers maintain the same dose during a switch.

For example, a patient stable on Mounjaro 10 mg who switches to Zepbound continues at Zepbound 10 mg with no washout or re-titration.

The most common reasons for switching:

• •Diagnosis change: a Mounjaro patient develops significant weight loss goals, or a Zepbound patient is diagnosed with Type 2 diabetes
• •Formulary change: an employer plan switches preferred tirzepatide brand mid-year
• •Self-pay: a cash-paying Mounjaro patient switches to Zepbound to access LillyDirect self-pay vials at lower cost
• •Medicare: a Mounjaro patient ages into Medicare and switches to Zepbound via the GLP-1 Bridge program (after July 2026)

If you're considering a switch, make that decision with your prescriber. Sprout Health's verified tirzepatide plans (2025 FDA warning for misleading compounded-drug marketing) are compounded, not Zepbound or Mounjaro; current branded availability is not confirmed.

Compare brand-name Zepbound options separately from compounded tirzepatide programs, then confirm the exact prescription, price and clinical follow-up before switching.

Can Mounjaro be prescribed for weight loss?

Off-label prescribing, using an FDA-approved drug for a condition not listed on its label, is legal in the US and common in medical practice.

Before Zepbound was approved in November 2023, providers routinely prescribed Mounjaro off-label for weight loss, and patients with commercial insurance sometimes got coverage through weight-management benefits.

After Zepbound's approval, off-label Mounjaro for weight loss became less defensible because an FDA-labeled alternative exists.

Important practical consequences of off-label prescribing for tirzepatide in 2026:

• •Insurance denial is likely: Commercial insurers and Medicare Part D typically deny claims when the diagnosis code doesn't match the FDA label. Mounjaro billed to a weight-loss-only diagnosis will usually be denied.
• •Savings cards may not apply: Lilly's Mounjaro Savings Card requires patients to have a Type 2 diabetes diagnosis on file; using the card for weight loss may violate the savings card terms.
• •Prior authorization becomes harder: Prior auth committees check the diagnosis against the drug label. Off-label combinations get flagged and often require appeals.
• •Your provider bears added liability: If an off-label prescription leads to a bad outcome, the prescriber's defense is weaker than for an on-label prescription.

FAQ

Are Zepbound and Mounjaro actually the same drug?

Yes. Both contain tirzepatide as the sole active ingredient at the same doses (2.5 to 15 mg). The formulation, injection device, and manufacturer (Eli Lilly) are identical.

The only difference is the brand name, which tracks the FDA-approved indication.

Is Zepbound better for weight loss than Mounjaro?

The molecule is identical, so the weight loss effect is identical. SURMOUNT-1 showed 20.9% body weight loss at 72 weeks on tirzepatide 15 mg.

That result applies to Mounjaro 15 mg and Zepbound 15 mg equally; the difference is only the FDA label and insurance coverage.

Can I use my Mounjaro Savings Card for Zepbound?

No. The cards are separate programs with separate eligibility. The Mounjaro Savings Card requires a Type 2 diabetes diagnosis. The Zepbound Savings Card requires a weight management or OSA prescription.

If you switch drugs, apply for the appropriate card.

Which one is cheaper if I'm paying cash?

Zepbound, by a meaningful margin. Zepbound vials through LillyDirect cost $299 (2.5 mg starter) to $449 (7.5-15 mg maintenance) per month.

Mounjaro does not have an equivalent self-pay vial program; cash-paying Mounjaro patients pay from $499/month for the pen, through LillyDirect self-pay or the savings card when a commercial plan does not cover it.

Will Medicare cover Zepbound or Mounjaro in 2026?

Mounjaro for type 2 diabetes and Zepbound for qualifying obstructive sleep apnea can follow ordinary Part D rules, subject to the exact plan.

For weight management, the separate Bridge includes Zepbound KwikPen only, at $50 per approved monthly supply if eligible.

It excludes Mounjaro, single-dose Zepbound vials and single-dose pens. CMS distinguishes these coverage routes; our Medicare coverage guide explains the next steps.

Is compounded tirzepatide the same as Zepbound or Mounjaro?

Chemically similar but not identical and not FDA-approved as Zepbound or Mounjaro. Compounded tirzepatide is made by 503A compounding pharmacies, not by Eli Lilly, and costs $99-$199/month at telehealth platforms.

FDA enforcement on compounded GLP-1s has tightened since tirzepatide was removed from the shortage list. See compounded tirzepatide for current status.

Sources

• •FDA Approves Lilly's Mounjaro (tirzepatide) Injection, Eli Lilly press release, May 13, 2022
• •FDA Approves New Medication for Chronic Weight Management, FDA press release, Zepbound approval, November 8, 2023
• •FDA Approves Zepbound for Obstructive Sleep Apnea, Eli Lilly press release, December 20, 2024
• •SURMOUNT-1 Trial Results (NEJM), Zepbound obesity trial, 20.9% weight loss at 72 weeks
• •SURPASS-2 Trial Results (NEJM), Mounjaro vs semaglutide head-to-head in Type 2 diabetes
• •SURMOUNT-OSA Trial Results (NEJM), Zepbound for obstructive sleep apnea
• •Zepbound prescribing information, FDA label, current version
• •Mounjaro Cost Information, Eli Lilly 2026 pricing
• •Mounjaro Savings Resources, Eli Lilly savings card program
• •CMS GLP-1 Bridge Program, Medicare Part D expansion, July 2026

Medical disclaimer: This article is for informational purposes only and does not constitute medical advice.

Tirzepatide is a prescription medication with FDA boxed warnings for thyroid C-cell tumors and contraindications including personal or family history of medullary thyroid carcinoma or MEN 2 syndrome.

Never start, stop, or switch a GLP-1 medication without consultation with a licensed healthcare provider. Pricing information reflects publicly available manufacturer and payer data as of April 2026 and may change.